Intrinsic value of Omeros - OMER

Previous Close

$19.25

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

  Value-price divergence*

0%

Previous close

$19.25

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of OMER stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  200.00
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  42
  67
  104
  155
  225
  318
  437
  587
  770
  991
  1,252
  1,554
  1,900
  2,291
  2,725
  3,204
  3,728
  4,294
  4,902
  5,552
  6,242
  6,972
  7,740
  8,546
  9,390
  10,272
  11,191
  12,148
  13,144
  14,180
  15,256
Variable operating expenses, $m
 
  83
  129
  192
  279
  393
  541
  726
  953
  1,227
  1,550
  1,924
  2,353
  2,836
  3,374
  3,967
  4,615
  5,316
  6,069
  6,874
  7,728
  8,631
  9,582
  10,580
  11,625
  12,716
  13,854
  15,039
  16,272
  17,554
  18,887
Fixed operating expenses, $m
 
  73
  75
  76
  78
  80
  82
  84
  87
  89
  91
  93
  95
  98
  100
  103
  105
  108
  111
  114
  116
  119
  122
  125
  128
  132
  135
  138
  142
  145
  149
Total operating expenses, $m
  101
  156
  204
  268
  357
  473
  623
  810
  1,040
  1,316
  1,641
  2,017
  2,448
  2,934
  3,474
  4,070
  4,720
  5,424
  6,180
  6,988
  7,844
  8,750
  9,704
  10,705
  11,753
  12,848
  13,989
  15,177
  16,414
  17,699
  19,036
Operating income, $m
  -60
  -89
  -99
  -113
  -132
  -156
  -186
  -224
  -270
  -325
  -389
  -463
  -548
  -643
  -749
  -865
  -993
  -1,130
  -1,278
  -1,435
  -1,602
  -1,779
  -1,964
  -2,159
  -2,363
  -2,576
  -2,798
  -3,030
  -3,270
  -3,520
  -3,780
EBITDA, $m
  -60
  -89
  -99
  -113
  -131
  -155
  -185
  -223
  -268
  -322
  -386
  -459
  -543
  -638
  -742
  -858
  -984
  -1,120
  -1,266
  -1,422
  -1,587
  -1,762
  -1,946
  -2,139
  -2,341
  -2,552
  -2,771
  -3,000
  -3,238
  -3,486
  -3,743
Interest expense (income), $m
  5
  6
  1
  2
  4
  6
  10
  14
  19
  26
  34
  44
  55
  67
  81
  97
  114
  133
  154
  176
  200
  225
  251
  279
  308
  339
  371
  404
  439
  475
  513
Earnings before tax, $m
  -67
  -95
  -100
  -115
  -136
  -162
  -196
  -238
  -289
  -351
  -423
  -507
  -602
  -710
  -830
  -963
  -1,107
  -1,263
  -1,432
  -1,611
  -1,802
  -2,003
  -2,216
  -2,438
  -2,672
  -2,915
  -3,169
  -3,434
  -3,709
  -3,995
  -4,293
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -67
  -95
  -100
  -115
  -136
  -162
  -196
  -238
  -289
  -351
  -423
  -507
  -602
  -710
  -830
  -963
  -1,107
  -1,263
  -1,432
  -1,611
  -1,802
  -2,003
  -2,216
  -2,438
  -2,672
  -2,915
  -3,169
  -3,434
  -3,709
  -3,995
  -4,293

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  45
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  67
  35
  54
  81
  118
  166
  229
  307
  403
  519
  656
  814
  995
  1,200
  1,428
  1,679
  1,953
  2,249
  2,568
  2,908
  3,270
  3,652
  4,055
  4,477
  4,919
  5,381
  5,862
  6,364
  6,885
  7,428
  7,992
Adjusted assets (=assets-cash), $m
  22
  35
  54
  81
  118
  166
  229
  307
  403
  519
  656
  814
  995
  1,200
  1,428
  1,679
  1,953
  2,249
  2,568
  2,908
  3,270
  3,652
  4,055
  4,477
  4,919
  5,381
  5,862
  6,364
  6,885
  7,428
  7,992
Revenue / Adjusted assets
  1.909
  1.914
  1.926
  1.914
  1.907
  1.916
  1.908
  1.912
  1.911
  1.909
  1.909
  1.909
  1.910
  1.909
  1.908
  1.908
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
  1.909
Average production assets, $m
  1
  2
  2
  4
  5
  8
  10
  14
  18
  24
  30
  37
  46
  55
  65
  77
  89
  103
  118
  133
  150
  167
  186
  205
  225
  247
  269
  292
  315
  340
  366
Working capital, $m
  44
  -2
  -2
  -4
  -5
  -8
  -10
  -14
  -18
  -24
  -30
  -37
  -46
  -55
  -65
  -77
  -89
  -103
  -118
  -133
  -150
  -167
  -186
  -205
  -225
  -247
  -269
  -292
  -315
  -340
  -366
Total debt, $m
  80
  8
  25
  49
  82
  126
  182
  253
  339
  443
  566
  709
  872
  1,056
  1,261
  1,487
  1,733
  2,000
  2,287
  2,594
  2,919
  3,263
  3,625
  4,005
  4,403
  4,819
  5,252
  5,703
  6,173
  6,661
  7,168
Total liabilities, $m
  105
  32
  49
  73
  106
  150
  206
  277
  363
  467
  590
  733
  896
  1,080
  1,285
  1,511
  1,757
  2,024
  2,311
  2,618
  2,943
  3,287
  3,649
  4,029
  4,427
  4,843
  5,276
  5,727
  6,197
  6,685
  7,192
Total equity, $m
  -37
  4
  5
  8
  12
  17
  23
  31
  40
  52
  66
  81
  100
  120
  143
  168
  195
  225
  257
  291
  327
  365
  405
  448
  492
  538
  586
  636
  689
  743
  799
Total liabilities and equity, $m
  68
  36
  54
  81
  118
  167
  229
  308
  403
  519
  656
  814
  996
  1,200
  1,428
  1,679
  1,952
  2,249
  2,568
  2,909
  3,270
  3,652
  4,054
  4,477
  4,919
  5,381
  5,862
  6,363
  6,886
  7,428
  7,991
Debt-to-equity ratio
  -2.162
  2.180
  4.590
  6.050
  6.970
  7.560
  7.950
  8.220
  8.410
  8.540
  8.630
  8.710
  8.760
  8.800
  8.830
  8.860
  8.880
  8.890
  8.910
  8.920
  8.930
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
  8.970
  8.970
  8.970
Adjusted equity ratio
  -3.727
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -67
  -95
  -100
  -115
  -136
  -162
  -196
  -238
  -289
  -351
  -423
  -507
  -602
  -710
  -830
  -963
  -1,107
  -1,263
  -1,432
  -1,611
  -1,802
  -2,003
  -2,216
  -2,438
  -2,672
  -2,915
  -3,169
  -3,434
  -3,709
  -3,995
  -4,293
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  1
  1
  1
  1
  2
  2
  3
  4
  5
  5
  7
  8
  9
  10
  12
  13
  15
  17
  19
  21
  23
  25
  27
  29
  32
  34
  37
Funds from operations, $m
  -58
  -95
  -100
  -115
  -135
  -162
  -195
  -237
  -287
  -348
  -420
  -503
  -598
  -705
  -824
  -955
  -1,098
  -1,253
  -1,420
  -1,598
  -1,787
  -1,987
  -2,197
  -2,418
  -2,649
  -2,891
  -3,143
  -3,405
  -3,678
  -3,961
  -4,256
Change in working capital, $m
  -6
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
Cash from operations, $m
  -52
  -94
  -99
  -114
  -134
  -159
  -192
  -233
  -283
  -343
  -414
  -496
  -589
  -695
  -813
  -943
  -1,086
  -1,240
  -1,405
  -1,582
  -1,770
  -1,969
  -2,179
  -2,399
  -2,629
  -2,870
  -3,120
  -3,382
  -3,654
  -3,936
  -4,230
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -5
  -7
  -8
  -9
  -10
  -12
  -13
  -15
  -17
  -19
  -21
  -23
  -25
  -27
  -29
  -32
  -34
New CAPEX, $m
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
Cash from investing activities, $m
  -16
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -5
  -7
  -8
  -10
  -12
  -14
  -15
  -19
  -21
  -23
  -25
  -28
  -30
  -33
  -35
  -38
  -41
  -44
  -47
  -50
  -53
  -57
  -60
Free cash flow, $m
  -68
  -95
  -100
  -115
  -136
  -162
  -196
  -238
  -289
  -350
  -422
  -506
  -602
  -709
  -829
  -961
  -1,106
  -1,262
  -1,430
  -1,609
  -1,800
  -2,002
  -2,214
  -2,437
  -2,670
  -2,913
  -3,167
  -3,432
  -3,707
  -3,993
  -4,290
Issuance/(repayment) of debt, $m
  24
  -72
  17
  24
  33
  44
  56
  71
  87
  104
  123
  143
  163
  184
  205
  226
  247
  267
  287
  306
  325
  344
  362
  380
  398
  416
  433
  451
  470
  488
  507
Issuance/(repurchase) of shares, $m
  41
  180
  102
  118
  139
  167
  202
  246
  299
  362
  437
  523
  620
  731
  853
  988
  1,134
  1,293
  1,463
  1,645
  1,838
  2,042
  2,256
  2,481
  2,716
  2,962
  3,218
  3,484
  3,761
  4,050
  4,349
Cash from financing (excl. dividends), $m  
  69
  108
  119
  142
  172
  211
  258
  317
  386
  466
  560
  666
  783
  915
  1,058
  1,214
  1,381
  1,560
  1,750
  1,951
  2,163
  2,386
  2,618
  2,861
  3,114
  3,378
  3,651
  3,935
  4,231
  4,538
  4,856
Total cash flow (excl. dividends), $m
  1
  13
  19
  27
  37
  49
  63
  79
  97
  116
  137
  159
  182
  205
  229
  252
  275
  298
  320
  342
  363
  384
  404
  424
  444
  464
  484
  504
  524
  545
  566
Retained Cash Flow (-), $m
  11
  -180
  -102
  -118
  -139
  -167
  -202
  -246
  -299
  -362
  -437
  -523
  -620
  -731
  -853
  -988
  -1,134
  -1,293
  -1,463
  -1,645
  -1,838
  -2,042
  -2,256
  -2,481
  -2,716
  -2,962
  -3,218
  -3,484
  -3,761
  -4,050
  -4,349
Prev. year cash balance distribution, $m
 
  45
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -122
  -83
  -91
  -103
  -118
  -140
  -167
  -202
  -246
  -299
  -363
  -438
  -525
  -624
  -736
  -859
  -995
  -1,143
  -1,303
  -1,475
  -1,658
  -1,852
  -2,056
  -2,272
  -2,498
  -2,734
  -2,980
  -3,237
  -3,505
  -3,783
Discount rate, %
 
  13.50
  14.18
  14.88
  15.63
  16.41
  17.23
  18.09
  19.00
  19.95
  20.94
  21.99
  23.09
  24.24
  25.46
  26.73
  28.07
  29.47
  30.94
  32.49
  34.11
  35.82
  37.61
  39.49
  41.47
  43.54
  45.72
  48.00
  50.40
  52.92
  55.57
PV of cash for distribution, $m
 
  -108
  -63
  -60
  -57
  -55
  -54
  -52
  -50
  -48
  -45
  -41
  -36
  -31
  -26
  -21
  -16
  -12
  -9
  -6
  -4
  -3
  -2
  -1
  -1
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  50.0
  1.7
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

FINANCIAL RATIOS  of  Omeros (OMER)

Valuation Ratios
P/E Ratio -12.6
Price to Sales 20.1
Price to Book -22.8
Price to Tangible Book
Price to Cash Flow -16.2
Price to Free Cash Flow -16.2
Growth Rates
Sales Growth Rate 200%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity -216.2%
Total Debt to Equity -216.2%
Interest Coverage -12
Management Effectiveness
Return On Assets -106.9%
Ret/ On Assets - 3 Yr. Avg. -283.6%
Return On Total Capital -200%
Ret/ On T. Cap. - 3 Yr. Avg. 165.4%
Return On Equity 212.7%
Return On Equity - 3 Yr. Avg. 224.2%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 95.2%
Gross Margin - 3 Yr. Avg. 60.3%
EBITDA Margin -147.6%
EBITDA Margin - 3 Yr. Avg. -2584.9%
Operating Margin -140.5%
Oper. Margin - 3 Yr. Avg. -2551.6%
Pre-Tax Margin -159.5%
Pre-Tax Margin - 3 Yr. Avg. -2698.4%
Net Profit Margin -159.5%
Net Profit Margin - 3 Yr. Avg. -2698.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

OMER stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the OMER stock intrinsic value calculation we used $42 million for the last fiscal year's total revenue generated by Omeros. The default revenue input number comes from 2016 income statement of Omeros. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our OMER stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 13.5%, whose default value for OMER is calculated based on our internal credit rating of Omeros, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Omeros.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of OMER stock the variable cost ratio is equal to 123.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $71 million in the base year in the intrinsic value calculation for OMER stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 7.7% for Omeros.

Corporate tax rate of 27% is the nominal tax rate for Omeros. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the OMER stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for OMER are equal to 2.4%.

Life of production assets of 10 years is the average useful life of capital assets used in Omeros operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for OMER is equal to -2.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-37 million for Omeros - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 45.716 million for Omeros is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Omeros at the current share price and the inputted number of shares is $0.9 billion.

RELATED COMPANIES Price Int.Val. Rating
MDCO Medicines 34.54 1.33  str.sell
PFE Pfizer 35.83 28.30  hold
ACHN Achillion Phar 4.28 0.89  str.sell
CAH Cardinal Healt 64.70 156.42  str.buy
MCK McKesson 146.21 795.25  str.buy

COMPANY NEWS

▶ ETFs with exposure to Omeros Corp. : October 18, 2017   [Oct-18-17 09:54AM  Capital Cube]
▶ What You Must Know About Omeros Corporations (OMER) Risks   [Oct-06-17 07:19PM  Simply Wall St.]
▶ ETFs with exposure to Omeros Corp. : October 3, 2017   [Oct-03-17 11:29AM  Capital Cube]
▶ ETFs with exposure to Omeros Corp. : September 22, 2017   [Sep-22-17 11:16AM  Capital Cube]
▶ ETFs with exposure to Omeros Corp. : September 12, 2017   [Sep-12-17 12:19AM  Capital Cube]
▶ ETFs with exposure to Omeros Corp. : August 31, 2017   [Aug-31-17 07:54PM  Capital Cube]
▶ Omeros Responds to Statnews.com Story   [Aug-23-17 11:00AM  Business Wire]
▶ Omeros Closes $68.3 Million Public Offering of Common Stock   [Aug-21-17 03:25PM  Business Wire]
▶ Omeros Announces Public Offering of Common Stock   [Aug-14-17 04:05PM  Business Wire]
▶ Omeros reports 2Q loss   [Aug-08-17 05:49PM  Associated Press]
▶ 3 Stocks That Could Put Nvidia's Returns to Shame   [Jul-25-17 06:30AM  Motley Fool]
▶ Omeros threatens to sue anonymous detractor   [Jul-06-17 05:45PM  American City Business Journals]
▶ Biotech Movers: BioCryst, Omeros, Radius Health   [Jul-03-17 09:24AM  TheStreet.com]
▶ 3 Stocks Wall Street Hasn't Noticed   [Jun-17-17 07:32AM  Motley Fool]
▶ These 3 Stocks Could Have Doubled Your Money This Year   [Jun-15-17 04:05PM  Motley Fool]
▶ 2 Longs And 2 Shorts To Watch   [Jun-14-17 02:09PM  Benzinga]
▶ Omeros: Can the Growth Story Continue?   [Jun-07-17 09:42AM  Motley Fool]
▶ 5 Top Stocks for June   [08:45AM  Motley Fool]
▶ 3 Stocks With Exelixis-Like Return Potential   [Jun-05-17 04:29PM  Motley Fool]
▶ ETFs with exposure to Omeros Corp. : June 1, 2017   [Jun-01-17 02:01PM  Capital Cube]
▶ ETFs with exposure to Omeros Corp. : May 22, 2017   [May-22-17 01:58PM  Capital Cube]
▶ Here's Why Omeros Corporation Is Surging Again Today   [May-17-17 12:03PM  Motley Fool]
▶ 3 Biotech Stocks I'd Buy Right Now   [May-15-17 04:31PM  Motley Fool]
▶ Here's Why Omeros Corporation Stock Is Falling Today   [May-11-17 12:28PM  Motley Fool]
▶ Omeros reports 1Q loss   [May-10-17 04:36PM  Associated Press]
▶ Biotech Movers: OncoMed, Incyte, Omeros   [Apr-17-17 09:28AM  TheStreet.com]
▶ 3 Biotech Stocks to Buy on Sale   [Apr-15-17 12:02PM  Motley Fool]
▶ Omeros to Present at the Needham Healthcare Conference   [Apr-03-17 07:00AM  Business Wire]
▶ Biotech Premarket Movers: Halozyme, Omeros, Aralez   [Mar-30-17 09:54AM  TheStreet.com]
▶ ETFs with exposure to Omeros Corp. : March 30, 2017   [Mar-29-17 08:34PM  Capital Cube]
▶ Top Biotech Stocks for Growth Investors   [04:21PM  Motley Fool]
▶ Top Biotech Stocks for Growth Investors   [04:21PM  at Motley Fool]
▶ Here's Why Omeros Corporation Stock Climbed Higher Today   [Mar-28-17 05:03PM  Motley Fool]
▶ 3 Stocks That Could Make You Rich   [12:24PM  Motley Fool]
▶ 3 Stocks That Could Make You Rich   [12:24PM  at Motley Fool]
▶ Omeros: Power in the Pipeline   [Mar-24-17 09:02AM  at Motley Fool]
Financial statements of OMER
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.